Status:
COMPLETED
The Effect of Switching the H1-antagonist Clemastine to Cetirizine in Premedication Regimens During Paclitaxel Treatment
Lead Sponsor:
Erasmus Medical Center
Conditions:
Solid Tumor
Eligibility:
All Genders
18+ years
Brief Summary
In this study the effect of substituting clemastine IV to cetirizine PO on the occurence of hypersensitivity reactions during paclitaxel chemotherapy will be investigated.
Detailed Description
This is a single arm before-after study with a historic control cohort to evaluate the effect of a policy change (i.e. substitution of clemastine IV for cetirizine PO) regarding the premedication sche...
Eligibility Criteria
Inclusion
- Age ≥ 18 years;
- Planned treatment with regular paclitaxel-based chemotherapy for any indication and with any dose
Exclusion
- Prior treatment with a paclitaxel-based regimen;
- Inability to orally ingest cetirizine
Key Trial Info
Start Date :
June 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 31 2023
Estimated Enrollment :
395 Patients enrolled
Trial Details
Trial ID
NCT06039137
Start Date
June 1 2022
End Date
October 31 2023
Last Update
September 25 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Erasmus University Medical Center
Rotterdam, South Holland, Netherlands, 3015 GD